CD38 and Miyoshi myopathy: Daratumumab, a first-in-class anti-CD38-mAb for the treatment of MM, is an attractive candidate for cooperating with CAR T cells as it can eliminate MM cells and simultaneously target CD38-positive immunosuppressive cells such as Tregs, regulatory B cells (Bregs) and MDSCs, reversing the suppressive immune microenvironment for CAR T cells (157, 181).